America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research for the treatment of breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the side effects of the AOH1996 drug compared to traditional chemotherapy treatments?
**Interview with Dr. Linda Malkas, Lead Researcher at City of Hope Hospital**
**Editor:** Thank you for joining us today, Dr. Malkas. Your team’s recent breakthrough in cancer treatment has garnered quite a lot of attention. Could you explain how the AOH1996 drug works against cancer cells?
**Dr. Malkas:** Thank you for having me. The foundation of AOH1996 lies in its ability to target a mutated version of the PCNA protein, which plays a crucial role in DNA replication and tumor growth. By disrupting the normal functioning of cancer cells, AOH1996 essentially ‘shuts down’ their reproductive cycle, much like a blizzard would temporarily disable an airport and halt the flow of planes, specifically those carrying cancer cells.
**Editor:** That’s a fascinating analogy! Your research indicated that this drug works against several types of cancers. Can you expand on the implications of that?
**Dr. Malkas:** Absolutely. Our studies have demonstrated that AOH1996 has shown effectiveness in a variety of cancer types, including breast, prostate, brain, and lung cancers, just to name a few. This wide-ranging efficacy suggests that we might be able to develop a more universal cancer treatment that minimizes the side effects typically associated with traditional chemotherapy.
**Editor:** You mentioned that these findings were tested on over 70 cancer cell lines. What were the main outcomes of these tests, and what are the next steps?
**Dr. Malkas:** The results were very promising. We found that AOH1996 selectively killed cancer cells without harming normal cells, indicating its potential for targeted therapy. The next step will involve advancing these findings into clinical trials in humans, which we hope will confirm the drug’s safety and efficacy in a clinical setting.
**Editor:** It sounds like there’s significant potential for this treatment. How do you see this impacting the future of cancer therapy?
**Dr. Malkas:** If clinical trials are successful, AOH1996 could represent a significant advancement in personalized cancer therapy. We envision a future where patients can receive tailored treatments that specifically target their type of cancer with fewer side effects, transforming the landscape of cancer treatment as we know it.
**Editor:** Thank you for sharing your insights, Dr. Malkas. We’re looking forward to following the progress of AOH1996 and the impact it could have on cancer treatments.
**Dr. Malkas:** Thank you for the opportunity! We are excited about the potential of our work and committed to moving forward.